全文获取类型
收费全文 | 48568篇 |
免费 | 2250篇 |
国内免费 | 1374篇 |
专业分类
耳鼻咽喉 | 280篇 |
儿科学 | 1084篇 |
妇产科学 | 603篇 |
基础医学 | 6747篇 |
口腔科学 | 1193篇 |
临床医学 | 3497篇 |
内科学 | 8153篇 |
皮肤病学 | 778篇 |
神经病学 | 5088篇 |
特种医学 | 1007篇 |
外国民族医学 | 6篇 |
外科学 | 3838篇 |
综合类 | 5303篇 |
现状与发展 | 2篇 |
一般理论 | 4篇 |
预防医学 | 2577篇 |
眼科学 | 578篇 |
药学 | 7348篇 |
4篇 | |
中国医学 | 1732篇 |
肿瘤学 | 2370篇 |
出版年
2023年 | 361篇 |
2022年 | 782篇 |
2021年 | 976篇 |
2020年 | 892篇 |
2019年 | 2073篇 |
2018年 | 1951篇 |
2017年 | 1280篇 |
2016年 | 911篇 |
2015年 | 1008篇 |
2014年 | 1916篇 |
2013年 | 2388篇 |
2012年 | 1993篇 |
2011年 | 2321篇 |
2010年 | 2020篇 |
2009年 | 2033篇 |
2008年 | 2069篇 |
2007年 | 2066篇 |
2006年 | 1720篇 |
2005年 | 1497篇 |
2004年 | 1425篇 |
2003年 | 1367篇 |
2002年 | 1128篇 |
2001年 | 1083篇 |
2000年 | 893篇 |
1999年 | 905篇 |
1998年 | 728篇 |
1997年 | 630篇 |
1996年 | 563篇 |
1995年 | 462篇 |
1994年 | 420篇 |
1993年 | 327篇 |
1992年 | 288篇 |
1991年 | 280篇 |
1990年 | 220篇 |
1989年 | 230篇 |
1987年 | 169篇 |
1986年 | 172篇 |
1985年 | 1022篇 |
1984年 | 1313篇 |
1983年 | 1043篇 |
1982年 | 1146篇 |
1981年 | 1134篇 |
1980年 | 890篇 |
1979年 | 866篇 |
1978年 | 586篇 |
1977年 | 508篇 |
1976年 | 578篇 |
1975年 | 527篇 |
1974年 | 386篇 |
1973年 | 385篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Clinical neurophysiology》2021,132(9):2003-2011
ObjectiveA large N20 and P25 of the median nerve somatosensory evoked potential (SEP) predicts short survival in amyotrophic lateral sclerosis (ALS). We investigated whether high frequency oscillations (HFOs) over N20 are enlarged and associated with survival in ALS.MethodsA total of 145 patients with ALS and 57 healthy subjects were studied. We recorded the median nerve SEP and measured the onset-to-peak amplitude of N20 (N20o-p), and peak-to-peak amplitude between N20 and P25 (N20p-P25p). We obtained early and late HFO potentials by filtering SEP between 500 and 1 kHz, and measured the peak-to-peak amplitude. We followed up patients until endpoints (death or tracheostomy) and analyzed the relationship between SEP or HFO amplitudes and survival using a Cox analysis.ResultsPatients showed larger N20o-p, N20p-P25p, and early and late HFO amplitudes than the control values. N20p-P25p was associated with survival periods (p = 0.0004), while early and late HFO amplitudes showed no significant association with survival (p = 0.4307, and p = 0.6858, respectively).ConclusionsThe HFO amplitude in ALS is increased, but does not predict survival.SignificanceThe enlarged HFOs in ALS might be a compensatory phenomenon to the hyperexcitability of the sensory cortex pyramidal neurons. 相似文献
3.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
4.
5.
6.
7.
目的:探讨D6S1043、D12S391基因座的基因多态性对主动攻击行为的影响。方法:应用聚合酶链反应技术结合毛细管电泳法对114例男性主动攻击行为者(研究组)及120名健康男性(对照组)进行D6S1043、D12S391基因座的基因型及等位基因检测,分析D6S1043、D12S391基因座多态性与主动攻击行为的相关性。结果:研究组D6S1043基因座中12~19基因型频率(13.16%)明显高于对照组(1.67%)(P0.05);两组等位基因频率差异无统计学意义;两组D12S391基因座的基因型及等位基因频率差异无统计学意义。结论:D6S1043基因座中12~19基因型可能主动攻击行为有关。 相似文献
8.
This is the first Japanese autopsy case of Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation with atypical TDP43 proteinopathy. Our case is important that presented clinically dysphagia and pathologically TDP-43 proteinopathy. TDP43 may play an important role of clinical presentation with LRRK2 G2019S mutation carriers. 相似文献
9.
10.